Sanofi's animal health Plan B: Bolt-on deals

Sanofi-Aventis aims to expand its animal health business through small acquisitions, the drugmaker's head said after plans collapsed to create the world's top joint venture in that area with Merck. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.